Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response

Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response. There were 61 patients wi...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of rheumatology Ročník 43; číslo 8; s. 1566
Hlavní autori:	Bauhammer, Jutta, Blank, Norbert, Max, Regina, Lorenz, Hanns-Martin, Wagner, Ulrich, Krause, Dietmar, Fiehn, Christoph
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Canada 01.08.2016
Predmet:	Adult Aged Autoantibodies - analysis Dermatomyositis - drug therapy Dermatomyositis - immunology Female Humans Immunosuppressive Agents - therapeutic use Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - immunology Male Middle Aged Myositis - drug therapy Myositis - immunology Retrospective Studies Ribonucleoproteins - immunology Rituximab - therapeutic use Severity of Illness Index Treatment Outcome Young Adult INTERSTITIAL LUNG DISEASE ANTISYNTHETASE ANTIBODIES Ro52 Jo1 POLYMYOSITIS
ISSN:	0315-162X, 1499-2752, 1499-2752
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!